Market Overview

UPDATE: Credit Suisse Upgrades GlaxoSmithKline to Neutral; Pricing Policy Impact Priced In

Share:
Related GSK
Why The Time Has Come To Buy Novartis
Earnings Scheduled For October 26, 2016
TiGenix Seeks $53 Million IPO For Promising Stem Cell Treatments (Seeking Alpha)

Credit Suisse raised its rating on GlaxoSmithKline (NYSE: GSK) from Underperform to Neutral.

Credit Suisse noted, "We upgrade rating of GSK to NEUTRAL from Underperform and increase our target price to Rs2,055 (from Rs1,870). Our positive stance is driven by the fact that the overhang of pricing policy is largely over, in our view, and the margins (ex-pricing policy impact) have bottomed out and should rebound. Under the new pricing policy, GSK drugs are now more affordable and should gain volume share. On the current portfolio under price control (25% of sales), the pricing policy allows players to take 10% price increase after one year and GSK should benefit."

GlaxoSmithKline closed at $43.85 on Wednesday.

Latest Ratings for GSK

DateFirmActionFromTo
Sep 2016PiperJaffrayInitiates Coverage onOverweight
Sep 2016Exane BNP ParibasDowngradesNeutralUnderperform
Aug 2016Argus ResearchMaintainsBuy

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (GSK)

View Comments and Join the Discussion!